HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

AbstractBACKGROUND:
The novel anticoagulant fondaparinux proved to be effective and safe in the postoperative prevention of venous thrombosis. Current phase III trials with this synthetic selective factor Xa inhibitor focus on its use in the treatment of patients with venous and arterial thrombosis. As with any anticoagulant therapy, there is a risk of bleeding complications; hence, a strategy to reverse the effects of fondaparinux is desirable. The aim of this study was to investigate whether recombinant factor VIIa (rFVIIa) could neutralize the anticoagulant effects of subcutaneously administered fondaparinux.
METHODS AND RESULTS:
In a randomized, placebo-controlled design, 16 healthy male subjects received either a single subcutaneous dose of fondaparinux (10 mg) and a single intravenous bolus of rFVIIa (90 microg/kg; n=8), fondaparinux and placebo (n=4), or placebo and rFVIIa (n=4). Fondaparinux (or placebo) was administered 2 hours before rFVIIa (or placebo). Injection of rFVIIa after fondaparinux normalized the prolonged activated partial thromboplastin and prothrombin times and reversed the decrease in prothrombin activation fragments 1+2 (F(1+2)), as observed with fondaparinux alone. Thrombin-generation time and endogenous thrombin potential, which were inhibited by fondaparinux, normalized up to 6 hours after rFVIIa injection.
CONCLUSIONS:
rFVIIa is capable of normalizing coagulation times and thrombin generation during fondaparinux treatment. The duration of this effect ranged from 2 to 6 hours after rFVIIa injection. These results suggest that rFVIIa may be useful to reverse the anticoagulant effect of fondaparinux in case of serious bleeding complications or need for acute surgery during treatment with fondaparinux.
AuthorsNick R Bijsterveld, Arno H Moons, S Matthijs Boekholdt, Benien E van Aken, Hein Fennema, Ron J G Peters, Joost C M Meijers, Harry R Büller, Marcel Levi
JournalCirculation (Circulation) Vol. 106 Issue 20 Pg. 2550-4 (Nov 12 2002) ISSN: 1524-4539 [Electronic] United States
PMID12427650 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticoagulants
  • Polysaccharides
  • Recombinant Proteins
  • Factor VII
  • Factor VIIa
  • Thrombin
  • fondaparinux
Topics
  • Adolescent
  • Adult
  • Anticoagulants (antagonists & inhibitors, blood)
  • Blood Coagulation
  • Double-Blind Method
  • Factor VII (analysis)
  • Factor VIIa (genetics, pharmacology)
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Polysaccharides (antagonists & inhibitors, blood)
  • Recombinant Proteins (pharmacology)
  • Thrombin (metabolism)
  • Thrombin Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: